



COMPANY OVERVIEW

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

NeoGenomics Schedules its Second Quarter Earnings Release for July 24, 2018

Jul 2 2018, 4:05 PM EDT

NeoGenomics Redeems 100% of Series A Redeemable Preferred Stock

Jun 25 2018, 4:05 PM EDT

PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions

Jun 1 2018, 8:00 AM EDT

STOCK OVERVIEW

Symbol	NEO
Exchange	Nasdaq
Market Cap	1.13b
Last Price	\$14.05
52-Week Range	\$7.08 - \$14.61

INVESTOR RELATIONS

William Bonello
Vice President, Strategy,
Corporate Development and
Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com

MANAGEMENT TEAM

Douglas M. VanOort

Chairman of the Board of Directors and Chief Executive Officer

Sharon Virag

Chief Financial Officer

Robert J. Shovlin

President, Clinical Services

George A. Cardoza

President, Pharma Services

Steven C. Jones

Executive Vice President

Denise E. Pedulla

General Counsel

Steven A. Ross

Vice President, Chief Information Officer

Jennifer M. Balliet

Vice President, Chief Culture Officer

Stephanie Bywater

Chief Compliance Officer

Steven G. Brodie, Ph.D.

Vice President of Operations

Kathryn B. McKenzie

Vice President - Finance, Principal Accounting Officer

Bill Bonello

Vice President, Strategy, Corporate Development and Investor Relations

NEOGENOMICS, INC.

12701 Commonwealth Dr.
Suite 9
Fort Myers, FL 33913

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.